 HOUSTON, Nov. 03, 2020 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. Nasdaq:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of 6.025 and each pre-funded warrant to purchase one share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of 6.024. The exercise price of each pre-funded warrant is 0.001 per share and the exercise price of each accompanying warrant to purchase common stock is 6.50 per share. 